Table 3. Summary of Studies About the Changes of Body Mass Index Standard Deviation Score During Gonadotropin-Releasing Hormone Agonist Therapy in Girls ^a.

Author (year), Reference	No	Treatment BMI-SDS for CA
		Baseline	Duration of Therapy, Mo	Final Visit	P Value
Current study
Intervention group	46	0.84 ± 1.01	0.92 ± 0.82 (12 mo)	___	NS
Control group	64	1.49 ± 1.28	1.49 ± 1.16 (12 mo)	___	NS
Arrigo (2004)
Intervention group	101	1.39 ± 1.07	0.61 ± 0.79 (12 mo)	0.11 ± 0.52	< 0.001
Control group					No control group
Yuan (2011)
Intervention group	57	0.35 ± 0.79	0.49 ± 0.72 (12 mo)	-0.12 ± 0.58	0.03
Control group	77	0.39 ± 0.89	___	0.29 ± 0.94	NA
Lee (2012)
Intervention group	38	0.58 ± 1.18	0.79 ± 0.84 (12 mo)	0.96 ± 0.83	< 0.05
Control group					No control group
Traggiai (2005)
Intervention group	29	1.7	1.8 (12 mo)	1.6	NR
Control group	45	2.1	1.6 (12 mo)	1	NR
Poomthavorn (2011)
Intervention group	47	1.26 ± 0.95	NR	0.16 ± 1	NA
Control group	11	NA
Oostdijk (1996)
Intervention group	30	1.7	1.824 mo	1.44	NS
Control group					No control group
Palmert (1999)
Intervention group	96	1.1 ± 0.1	0.9 ± 0.136 mo	0.9 ± 0.1	NS
Control group					No control group

^a Abbreviations: BMI-SDS for CA, body mass index standard deviation score for chronological age; NA, not available; NS, not significant.